SION · Sionna Therapeutics, Inc.
$3.60
-5.26% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-1.6
Dividend yield
0.0%
Beta
—
Avg volume
2M
Employees
0K
Daily Change %
-5.26%
5 Days Change
-2.31%
10 Days Change
-13.24%
30 Days Change
-31.03%
60 Days Change
-32.02%
Month to Day Change
-25.49%
Year to Day Change
-90.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SION
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-15
Latest call per bank · past 12 months
RBC Capital
Underperform$24.00
+566.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | Wedbush | Maintains | Neutral | $5.00 → $6.00 |
| 2026-08-11 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-08-11 | Wedbush | Downgrade | Outperform → Neutral | $53.00 → $5.00 |
| 2026-08-10 | BTIG | Downgrade | Buy → Neutral | $0.00 |
| 2026-08-07 | Guggenheim | Maintains | Buy | $50.00 → $60.00 |
| 2026-05-26 | Citizens | Reiterates | Market Outperform | $63.00 |
| 2026-05-20 | Freedom Broker | Downgrade | Buy → Hold | $38.00 |
| 2026-05-18 | Stifel | Maintains | Buy | $44.00 → $55.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 24 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 36.4% below the 50-day MA ($5.66).
- bearish: Price vs 200-day MA: Trading 88.4% below the 200-day MA ($30.96).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.24) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($3.60).
SION Price Chart
Loading chart for SION…
Fundamentals
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.